Transmission of drug-resistant HIV type 1 strains in HAART-naive patients: A 5-year retrospective study in sicily, Italy

AIDS Research and Human Retroviruses

Volumn 26, Issue 9, 2010, Pages 961-965

  Bonura, Filippa ^a   Tramuto, Fabio ^a   Vitale, Francesco ^a   Perna, Anna Maria ^a   Viviano, Enza ^a   Romano, Nino ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CHILD; EUROPE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; ITALY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS STRAIN; VIRUS TRANSMISSION; DRUG EFFECTS; GENETICS; HIV INFECTIONS; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; PRESCHOOL CHILD; TRANSMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PREVALENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SICILY; YOUNG ADULT;

EID: 77956361317     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0250     Document Type: Article

References (38)

1. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
2. Mouton Y, Alfandari S, Valette M, et al.: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA. AIDS 1997;11:F101-105.
3. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
4. De Luca A, Weidler J, Di Giambenedetto S, et al.: Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure. J Acquir Immune Defic Syndr 2007;45:411-417.
5. Vandamme AM, Van Laethem K, and De Clercq E: Managing resistance to anti-HIV drugs: An important consideration for effective disease management. Drugs 1999;57:337-361.
6. Ross L, Lim ML, Liao Q, et al.: Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-näve HIV-infected individuals from 40 United States cities. HIV Clin Trials 2007;8:1-8.
7. Wensing AM, van de Vijver DA, Angarano G, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 2005;192:958-966.
8. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
9. Grubb JR, Singhatiraj E, Mondy K, et al.: Patterns of primary antiretroviral drug resistance in antiretroviral-näve HIV-1-infected individuals in a midwest university clinic. AIDS 2006;20:2115-2116.
10. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
11. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1. Top HIV Med 2008;16:138-145.
12. Stanford University-HIV Drug Resistance Database. http://hivdb.stanford. edu.
13. Schneider E, Whitmore S, Glynn KM, et al.; Centers for Disease Control and Prevention (CDC): Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged
14. StataCorp. 2009. Stata Statistical Software: Release 11. StataCorp LP, College Station, TX.
15. Geretti AM: Epidemiology of antiretroviral drug resistance in drug-näve persons. Curr Opin Infect Dis 2007;20:22-32.
16. Descamps D, Chaix ML, André P, et al.: French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-näve chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005;38:545-552.
17. SPREAD programme: Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008; 22:625-635.
18. Alteri C, Svicher V, Gori C, et al.: Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients näve to the antiretroviral drugs. BMC Infect Dis 2009;9:111.
19. Babic DZ, Zelnikar M, Seme K, et al.: Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-näve patients in Slovenia, 2000-2004. Virus Res 2006;118:156-163.
20. Poggensee G, Kücherer C, Werning J, et al.: Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med 2007;8:511-519.
21. Payne BA, Nsutebu EF, Hunter ER, et al.: Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. J Antimicrob Chemother 2008;62:464-468.
22. Santoro MM, Ciccozzi M, Alteri C, et al.: Characterization of drug-resistance mutations in HIV type 1 isolates from drugnäve and ARV-treated patients in Bulgaria. AIDS Res Hum Retroviruses 2008;24:1133-1138.
23. Rahim S, Fredrick LM, da Silva BA, et al.: Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-näve subjects screening for two clinical trials in North America and Western Europe. HIV Clin Trials 2009;10:94-103.
24. Agwale SM, Zeh C, Paxinos E, et al.: Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-näve Nigerian patients. AIDS Res Hum Retroviruses 2006;22:22-26.
25. Rangel HR, Garzaro DJ, Torres JR, et al.: Prevalence of antiretroviral drug resistance among treatment-näve and treated HIV-infected patients in Venezuela. Mem Inst Oswaldo Cruz 2009;104:522-525.
26. Eshleman SH, Laeyendecker O, Parkin N, et al.: Antiretroviral drug susceptibility among drug-näve adults with recent HIV infection in Rakai, Uganda. AIDS 2009;27:845-852.
27. Janin N, Sopheak N, Regis MP, et al.: Low prevalence of drug resistance transmitted virus in HIV Type 1-infected ARV-näve patients in Cambodia. AIDS Res Hum Retroviruses 2009;25:543-545.
28. Tee KK, Kamarulzaman A, and Ng KP: Low prevalence of genotypic drug resistance mutations among antiretroviralnäve HIV type 1 patients in Malaysia. AIDS Res Hum Retroviruses 2006;22:121-124.
29. Lapadula G, Izzo I, Gargiulo F, et al.: Updated prevalence of genotypic resistance among HIV-1 positive patients näve to antiretroviral therapy: A single center analysis. J Med Virol 2008;80:747-753.
30. Violin M, Velleca R, Cozzi-Lepri A, et al.: Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001. J Acquir Immune Defic Syndr 2004;36:761-764.
31. Nijhuis M, van Maarseveen NM, and Boucher CA: HIV protease resistance and viral fitness. Curr Opin HIV AIDS 2007;2:108-115.
32. Devereux HL, Emery VC, Johnson MA, et al.: Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 2001;65:218-224.
33. Land S, McGavin K, Birch C, et al.: Reversion from zidovudine resistance to sensitivity on cessation of treatment. Lancet 1991;338:830-831.
34. Little SJ, Frost SD, Wong JK, et al.: Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008;82:5510-5518.
35. Suligoi B, Boros S, Camoni L, et al.: Aggiornamento dei casi di AIDS e delle nuove diagnosi di infezioni da HIV in Italia al 31 dicembre 2007. Not Ist Super Sanita 2008;21(5) Suppl. 1.
36. Metzner KJ, Rauch P, Walter H, et al.: Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005;19:1819-1825.
37. Metzner KJ, Giulieri SG, Knoepfel SA, et al.: Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-näve and -adherent patients. Clin Infect Dis 2009;48:239-247.
38. Johnson JA, Li JF, Wei X, et al.: Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-näve populations and associate with reduced treatment efficacy. PLoS Med 2008;5:e158.